DALLAS – Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced publication of new preclinical data for TSHA-104 in...
Latest News
DALLAS, TX — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced...
DALLAS, TX — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced updates to its TSHA-102 program in clinical evaluation for the treatment of Rett...
DALLAS – Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it has been granted orphan drug...
A research team led by a University of Iowa investigator has generated DNA-like compounds that effectively inhibit the cells responsible for systemic lupus erythematosus — the most common and serious form of lupus. There currently is no cure for this chronic autoimmune condition that damages the skin, joints and internal...
SAN ANTONIO, Texas — The 50 families stretch from the Netherlands and the United Kingdom to the United States and China. Each family has a child who is paralyzed from a mutation in a single gene named Contactin-Associated Protein 1 (Cntnap1). The children are locked inside their bodies, unable to...
AyuVis Research Inc., a TechFW client, has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its small molecule drug AVR-48 for the prevention of bronchopulmonary dysplasia or BPD. AVR-48 works to modulate the immune system by decreasing the inflammatory response to MV and oxygen...
It’s not easy for Crystal Martinez to keep on top of her busy schedule. Along with her schoolwork as a student at Pocono Mountain West High School, she also has a hectic schedule of singing engagements extending through the summer, including one that will be before 100,000 people at the...
Hattiesburg, Miss. – A teenager in Mississippi is living with a disease so rare that less than 20 people worldwide have ever been diagnosed with it. Symptoms for 16-year-old Trey Garczynski started when he was 11 years old. “I was just walking around, but just a few minutes later, my...
HAMPTON, Conn. — A parent’s worst nightmare is that their child will suffer from a life-threatening disease with no cure on the horizon. But a family in Hampton said it’s putting all of its hopes into an experimental stem cell treatment and is traveling to Germany for the surgery. In...